DexCom, Inc.

DexCom, Inc.

DXCM

$82.97

Updated: 03/11/2026, 22:26:32

Market Cap
$30.94B
Sector
Healthcare
Industry
Medical - Devices
Country
US

No historical data available

Company Profile

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

USD
NASDAQ
CEO: Jacob Steven Leach
Employees: 11,050
https://www.dexcom.com
Asset Summaries
Latest generated summaries for DXCM

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
DXCM-10-k-fy2025.html2.4 MBtext/htmlENFiled 12/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 67 KPI observations

Revenue

$4.7B

FY 2025 · Reported

Net income

$0.8B

FY 2025 · Reported

Gross margin

60.1%

FY 2025 · Calculated

Free cash flow

$1.1B

FY 2025 · Calculated

R&D intensity

12.9%

FY 2025 · Calculated

Share repurchases

$0.5B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

CGM product portfolio
Stelo launch

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
3 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Malaysia manufacturing network

Malaysia · Manufacturing Partner Country

100% confidence
Functions
Manufacturing, Supply Chain
Ownership
Outsourcing Partner
Products / scope
Not disclosed by country
Share of production
Not disclosed by country
Reported revenue share
Not disclosed by country
Manufacturing footprint. the majority of our manufacturing operations are conducted at facilities located in Mesa, Arizona, and Malaysia and limited manufacturing operations in San Diego, California

Malaysia

Malaysia manufacturing network

the majority of our manufacturing operations are conducted at facilities located in Mesa, Arizona, and Malaysia and limited manufacturing operations in San Diego, California

Mesa, Arizona

Mesa, Arizona manufacturing network

the majority of our manufacturing operations are conducted at facilities located in Mesa, Arizona, and Malaysia and limited manufacturing operations in San Diego, California

San Diego, California

San Diego, California manufacturing network

the majority of our manufacturing operations are conducted at facilities located in Mesa, Arizona, and Malaysia and limited manufacturing operations in San Diego, California

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

US private payor coverage and Medicaid reach

As of Dec 31, 2025: Medicaid coverage in ~48 states; all eight largest US private payors have CGM coverage policies and contracted rates; certain international market coverage.

95%
Source evidence
“We also have coverage under certain international markets and Medicaid coverage in approximately 48 states as of December 31, 2025.”

Medicare coverage scope for CGM

Medicare covers CGM under the DME benefit; April 2023 LCD extended coverage to all insulin users and non-insulin patients with problematic hypoglycemia.

95%
Source evidence
“The Local Coverage Determination, or LCD, that CMS released in April 2023 extended Medicare CGM coverage to all patients using insulin.”

Third-party payor reimbursement reliance

Most customers rely on third-party payors (government programs and private insurance) to cover product cost

90%
Source evidence
“Most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of the G6, G7, G-7 15 Day, Dexcom One, and Dexcom ONE+.”

Direct sales and distributor network

Direct sales force in North America, Asia Pacific, Europe and Middle East plus distribution arrangements with distributors/wholesalers

90%
Source evidence
“We currently employ sales and marketing personnel for the direct sale and marketing of certain of our products in North America, Asia Pacific, Europe and the Middle East.”

CGM product portfolio

G6, G7, G-7 15 Day, Dexcom One, Dexcom ONE+; Stelo launched in the US in 2024

95%
Source evidence
“Most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of the G6, G7, G-7 15 Day, Dexcom One, and Dexcom ONE+.”

Stelo launch

Stelo launched in the United States in 2024; expanding distribution capabilities

90%
Source evidence
“In 2024, we launched Stelo in the United States and are expanding distribution capabilities for its sales.”

Operations and dependencies

Manufacturing footprint

Majority of manufacturing at Mesa, Arizona and Malaysia; limited manufacturing in San Diego, California

95%
Source evidence
“the majority of our manufacturing operations are conducted at facilities located in Mesa, Arizona, and Malaysia and limited manufacturing operations in San Diego, California”

Single-source suppliers for key components

As of Dec 31, 2025, single-source suppliers include ASICs for transmitters, applicator seals, and polymers for sensor membranes.

95%
Source evidence
“those single sources include but are not limited to suppliers of application-specific integrated circuits used in our transmitters, seals used for the applicator and certain polymers used to synthesize polymeric membranes for our sensors”

Single/sole-source components

Relies on single/sole sources for the application-specific integrated circuit in the transmitter and certain polymers used to synthesize polymeric biointerface membranes

90%
Source evidence
“we also rely on single and/or sole sources for certain components and materials used in manufacturing, such as for the application-specific integrated circuit that is incorporated into the transmitter and certain polymers used to synthesize the polymeric biointerface membranes”

Positioning and strategy

International manufacturing expansion — Malaysia and Ireland

Investments in build-out of manufacturing facility in Malaysia and construction of a new facility in Ireland

90%
Source evidence
“including investments in the international expansion of our sales efforts and the build-out of our manufacturing facility in Malaysia and the construction of a new facility in Ireland”

Patent portfolio protecting membrane and sensor technologies

Issued patents expire from 2026 to 2044, protecting core membrane and sensor technologies for CGM.

95%
Source evidence
“Our issued patents as of December 31, 2025 are set to expire over a range of years, from 2026 with respect to some of our earlier patents, to 2044, subject to any extensions.”

Expanded Medicare coverage criteria

April 2023 LCD extends Medicare CGM coverage to patients using any insulin and non-insulin patients with history of problematic hypoglycemia

90%
Source evidence
“The Local Coverage Determination, or LCD, that CMS released in April 2023 extends Medicare CGM coverage to patients who use any insulin. Further, the LCD also allows coverage for patients not taking insulin if the patient has a history of problematic hypoglycemia.”

Risks, financing, and outlook

Convertible senior notes outstanding

Company has indebtedness in the form of convertible senior notes.

90%
Source evidence
“We have indebtedness in the form of convertible senior notes, which could adversely affect our financial health and our ability to respond to changes in our business.”

Indenture does not restrict additional debt

Not restricted under the Notes indenture from incurring additional debt, which could diminish ability to pay Notes

90%
Source evidence
“We are not restricted under the terms of the indenture governing the Notes from incurring additional debt, securing existing or future debt, recapitalizing our debt”

Convertible notes and capped call transactions (2028 Notes)

2028 Notes with capped call transactions expected to reduce dilution; counterparty risk on capped calls is unsecured

90%
Source evidence
“The 2028 Capped Calls are generally expected to reduce the potential dilution to stockholders upon any conversion of the 2028 Notes”

Expected decline in Medicare CGM reimbursement from 2028

Company expects Medicare reimbursement for CGM systems to decrease beginning in 2028 due to competitive bidding.

95%
Source evidence
“As a result, we expect that Medicare reimbursement for our CGM systems will decrease beginning in 2028.”

Expected Medicare reimbursement decline

Company expects Medicare reimbursement for CGM systems to decrease beginning in 2028

90%
Source evidence
“As a result, we expect that Medicare reimbursement for our CGM systems will decrease beginning in 2028.”

Expected expansion of operations and hiring

Expects to continue expanding operations; recruiting and retaining personnel critical to success

85%
Source evidence
“We expect to continue to expand our operations and grow our research and development, manufacturing, sales and marketing, product development and administrative operations.”

Medicare DMEPOS competitive bidding program extended to CGMs

In late 2025, CMS extended DMEPOS competitive bidding to CGMs with contracting in 2027 and payment changes from Jan 1, 2028; company expects Medicare reimbursement to decrease beginning 2028.

95%
Source evidence
“In late 2025, CMS extended the Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) competitive bidding program to include our CGMs and receivers beginning with contracting in 2027, and payment changes effective January 1, 2028.”

One Big Beautiful Bill Act Medicaid changes

Budget reconciliation bill signed July 4, 2025 includes Medicaid changes; CBO preliminary estimates: $1 trillion Medicaid spending reduction and at least 11.8 million more uninsured by 2034

90%
Source evidence
“Congressional Budget Office, or CBO, preliminary estimates show that the Medicaid provisions would reduce Medicaid spending by $1 trillion and will increase the number of people without health insurance by at least 11.8 million by 2034.”

QMSR replacing Quality System Regulation effective February 2, 2026

FDA's QSR is being superseded by the QMSR effective February 2, 2026, aligned with international quality management standards.

90%
Source evidence
“the Quality System Regulation, or QSR, which is in the process of being superseded by the new Quality Management System Regulation, or QMSR, becoming effective February 2, 2026”

Direct-to-consumer marketing and social media regulatory scrutiny

Direct-to-consumer marketing and social media may draw additional scrutiny from FDA, FTC, HHS-OCR; comparative claims risk false-advertising suits

90%
Source evidence
“Our efforts to promote our products via direct-to-consumer marketing and social media initiatives may subject us to additional scrutiny... under the oversight of the FDA, FTC, HHS-OCR, or others.”

Medicare competitive bidding program for CGMs

CMS extended DMEPOS competitive bidding to CGMs; contracting beginning in 2027, payment changes effective 2028; ~10 contracts anticipated; pricing at 75th percentile of winning bids; monthly rental payments phased in

95%
Source evidence
“In late 2025, CMS extended the DMEPOS competitive bidding program to include our CGMs and receivers, with contracting beginning in 2027 and payment changes taking effect in 2028.”

History of operating losses; possible future losses

Prior significant operating losses; expects R&D and G&A increases tied to next-gen sensors, transmitters, receivers and clinical trials

95%
Source evidence
“We have incurred significant operating losses in the past. We expect our research and development expenses to increase in connection with our clinical trials and other development activities related to our products, including our next-generation sensors, transmitters and receivers”

Key-person dependency on CEO Jake Leach

Depends to a significant degree on senior management, especially CEO Jake Leach; intense competition for skilled personnel

95%
Source evidence
“We depend to a significant degree on our senior management, especially Jake Leach, our President and Chief Executive Officer.”

Debt servicing and refinancing risk

Servicing debt requires significant cash; may need to refinance Notes or other debt on unfavorable terms

90%
Source evidence
“We may not maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on (as well as any cash due upon conversion of) our debt, including the Notes.”

Concentrated manufacturing facility risk

Facility-specific risks: Arizona drought/water supply, Malaysia reclaimed wetland and political stability, California earthquake and wildfire exposure

90%
Source evidence
“Our Arizona facility may confront water supply issues resulting from the ongoing drought in the Western United States and our Malaysia facility may confront issues related to its construction on a reclaimed wetland and the political stability of the Malaysia government.”

Pricing pressure from payors and competitive bidding

Continuing decreasing product prices expected due to Medicare reimbursement changes and managed care/third-party payor pricing pressure

90%
Source evidence
“We have experienced, and anticipate that we will continue to experience, decreasing prices for our products due to future reimbursement changes under Medicare and pricing pressure from managed care organizations and other third-party payors.”

Financing needs and possible additional financings

May conduct additional financings; financing may be dilutive to stockholders or require security interest in assets

90%
Source evidence
“Although we raised substantial net proceeds through the private sale of our convertible notes, we could require funds to continue the commercialization of our current products”

Patient receivable collection risk

Uncollectible uninsured and patient due accounts could adversely affect results; most customers rely on third-party payors

90%
Source evidence
“As most of our customers rely on third-party payors, including private health insurance plans, to cover the cost of our products, there has been, and may continue to be, a shift in financial responsibility to our customers”

Cybersecurity and data privacy risk

Cyber incidents and evolving privacy/data protection laws could result in penalties, litigation, and business disruption.

90%
Source evidence
“Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA”

Reimbursement and managed care risks

Coverage gaps, reimbursement administrative challenges, managed care consolidation, and health care reform could negatively impact revenue.

90%
Source evidence
“If we are unable to obtain adequately broad coverage or reimbursement for our products or any future products from third-party payors, our revenue may be negatively impacted.”

FDA warning letter and regulatory compliance risk

Ongoing regulatory non-compliance, including the FDA warning letter, could result in product restrictions or withdrawal from the market.

90%
Source evidence
“If we, our suppliers, or our distributors fail to comply with ongoing regulatory requirements, including responding to the FDA warning letter, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market.”

Outsourced services exposure

Outsources certain services including inside sales, transaction processing, accounting, IT and manufacturing

85%
Source evidence
“We also outsource certain services to other parties, including inside sales, certain transaction processing, accounting, information technology, manufacturing, and other areas.”

Country-of-origin reporting uncertainty under competitive bidding

Competitive bidding includes a country-of-origin question; impact unclear given offshore manufacturing facilities

85%
Source evidence
“the new bidding system will contain a “country of origin” question to obtain information on where products are manufactured; however, it is unclear how CMS intends to use this information. Given that we maintain offshore manufacturing facilities, country of origin reporting could have an impact on our business.”

Notes conversion dilution and short-selling pressure

Conversion of Notes dilutes ownership and could depress stock price; may encourage short selling

85%
Source evidence
“the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions”

Equity investment portfolio risk

Invests in early to late-stage companies; subject to loss of invested capital and fair value changes

85%
Source evidence
“We are subject to risks associated with our equity investments including partial or complete loss of invested capital, and significant changes in the fair value of this portfolio could adversely impact our financial results.”

Acquisition integration risk

Acquisition risks include integration difficulties, potential impairment charges, dilution; currently no commitments or agreements

85%
Source evidence
“we could acquire or make other investments in complementary companies, products or technologies... although we currently have no commitments or agreements relating to any of these types of transactions”

Workforce reorganization risk

May conduct workforce reorganizations; cannot guarantee specific long-term cost savings

80%
Source evidence
“We may undertake reorganizations of our workforce, which may result in a temporary reduction in the number of employees in certain locations.”

Material exposure graph

Third-party payors (Medicare, Medicaid, private insurers)
Revenue Exposure

Most customers depend on third-party payor coverage; reimbursement decisions and rates drive product demand and pricing.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“Most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of the G6, G7, G-7 15 Day, Dexcom One, and Dexcom ONE+.”
CMS DMEPOS Competitive Bidding Program
Regulatory Exposure

CMS competitive bidding extension to CGMs is expected to reduce Medicare reimbursement beginning 2028, directly affecting DexCom pricing and revenue.

Relevance 95·Dependency 85·Confidence 95
Source evidence
“we expect that Medicare reimbursement for our CGM systems will decrease beginning in 2028”
CMS DMEPOS competitive bidding program
Revenue Exposure

Competitive bidding set at 75th percentile of winning bids with monthly rental bundling is expected to decrease Medicare reimbursement for CGM systems beginning 2028.

Relevance 95·Dependency 85·Confidence 95
Source evidence
“the bid process is expected to result in lower Medicare reimbursement for CGM systems”
Mesa, Arizona; Malaysia; San Diego, California
Manufacturing Dependency

Majority of manufacturing concentrated in Mesa, Arizona and Malaysia with limited alternates; disruption would impair production and sales.

Relevance 90·Dependency 85·Confidence 95
Source evidence
“our products are manufactured at certain facilities, with limited alternate facilities”
Medicare beneficiaries
Revenue Exposure

Medicare coverage under the DME benefit, expanded by the April 2023 LCD to all insulin users, is a key driver of US demand.

Relevance 90·Dependency 80·Confidence 95
Source evidence
“Medicare covers the CGM system, which includes both the receiver device and the supplies necessary for the use of the device, under the Durable Medical Equipment, or DME, benefit category”
Polymers for sensor polymeric membranes
Supplier Dependency

Single-source polymers used to synthesize sensor membranes create supply disruption vulnerability for sensor production.

Relevance 85·Dependency 90·Confidence 95
Source evidence
“those single sources include but are not limited to suppliers of application-specific integrated circuits used in our transmitters, seals used for the applicator and certain polymers used to synthesize polymeric membranes for our sensors”
Application-specific integrated circuits (ASICs) for transmitters
Supplier Dependency

Transmitter ASICs are single-sourced, exposing transmitter manufacturing to supply disruption and price fluctuation.

Relevance 85·Dependency 90·Confidence 95
Source evidence
“suppliers of application-specific integrated circuits used in our transmitters”
Single/sole-source ASIC and membrane polymers
Supplier Dependency

Sole/single-source components (transmitter ASIC, biointerface membrane polymers) create supply interruption risk that is hard to replace due to custom design and regulatory requalification.

Relevance 85·Dependency 80·Confidence 90
Source evidence
“we may have difficulty locating and qualifying alternative suppliers for our single-source supplies”
US private third-party payors
Customer Exposure

Coverage and reimbursement from the eight largest private payors, with contracted rates, is an important element of commercial success.

Relevance 85·Dependency 80·Confidence 90
Source evidence
“As of December 31, 2025, the eight largest private third-party payors in the United States, in terms of the number of covered lives, have issued coverage policies for the category of CGM devices”
FDA warning letter
Regulatory Exposure

Failure to respond to the FDA warning letter could lead to product restrictions or market withdrawal, directly affecting revenue.

Relevance 80·Dependency 75·Confidence 90
Source evidence
“If we, our suppliers, or our distributors fail to comply with ongoing regulatory requirements, including responding to the FDA warning letter, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market”
One Big Beautiful Bill Act
Revenue Exposure

Medicaid cuts and stricter eligibility may reduce the number of individuals eligible for coverage who could use DexCom products.

Relevance 80·Dependency 60·Confidence 90
Source evidence
“Decreased federal funding and stricter eligibility requirements may result in more restrictive Medicaid programs at the state level and fewer individuals eligible for coverage, which could have an adverse impact on the number of individuals who seek to use our products and services.”
Direct sales force and distributors/wholesalers
Customer Exposure

Revenue depends on direct sales teams across four regions plus distributor arrangements to reach underrepresented regions and distributor-exclusive payors.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“We have also entered into distribution arrangements to leverage existing distributors (including wholesalers) already engaged in the distribution of drugs, devices and/or products in the diabetes marketplace.”
Third-party payor insured patients
Customer Exposure

Most customers rely on third-party payors (private health insurance) to cover product costs; shifts to patient responsibility create collection and demand risk.

Relevance 70·Dependency 75·Confidence 90
Source evidence
“As most of our customers rely on third-party payors, including private health insurance plans, to cover the cost of our products”
Cybersecurity and data privacy
Legal Exposure

Cyber incidents could compromise confidential data, trigger HIPAA liability, litigation, and government inquiries, disrupting business.

Relevance 70·Dependency 65·Confidence 90
Source evidence
“Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories”
April 2023 Medicare Local Coverage Determination
Demand Driver

Expanded Medicare coverage criteria (any-insulin users and problematic hypoglycemia patients) enlarge the eligible patient population and support demand.

Relevance 70·Dependency 55·Confidence 90
Source evidence
“The Local Coverage Determination, or LCD, that CMS released in April 2023 extends Medicare CGM coverage to patients who use any insulin.”
Malaysia
Manufacturing Dependency

Build-out of a manufacturing facility in Malaysia is a disclosed capital investment and asset-value risk if macro conditions deteriorate.

Relevance 60·Dependency 50·Confidence 85
Source evidence
“the build-out of our manufacturing facility in Malaysia and the construction of a new facility in Ireland”
FDA/FTC marketing and advertising regulation
Regulatory Exposure

Direct-to-consumer marketing and social media promotion is subject to FDA, FTC, and HHS-OCR scrutiny; comparative claims risk litigation.

Relevance 55·Dependency 55·Confidence 90
Source evidence
“may subject us to additional scrutiny of our practices of effective communication of risk information, benefits or claims, under the oversight of the FDA, FTC, HHS-OCR, or others.”
Stelo
Revenue Exposure

Stelo, launched in the US in 2024, is a growth vector requiring expanded distribution capabilities.

Relevance 55·Dependency 40·Confidence 85
Source evidence
“In 2024, we launched Stelo in the United States and are expanding distribution capabilities for its sales.”
Full company information
Latest profile, trading, valuation, and identifier data stored for DXCM.
Share price
$82.97
Market cap
$30.94B
Exchange
NASDAQ
Currency
USD
CEO
Jacob Steven Leach
Employees
11,050
IPO date
14/04/2005
Beta
1.477
Last dividend
$0.00
Day range
$82.81 – $85.18
52-week range
$54.11 – $92.59
1-day performance
-2.11%
1-year performance
53.34%
Current drawdown (1Y)
-10.39%
CIK
0001093557
CUSIP
252131107
ISIN
US2521311074
Created
07/12/2025, 03:41:43
Last update
03/11/2026, 22:26:32

Track DexCom, Inc. with an AI analyst

See which prediction-market events move DXCM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to DXCM from your Railway `news_articles` table.